Clinical efficacy of vardenafil on ED patients with kidney-yang or -yin deficiency or liver-qi stasis.
- Author:
He-ping XU
1
;
Er-po TIAN
;
Jie XUE
;
Ming-liang ZHANG
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Erectile Dysfunction; drug therapy; Humans; Imidazoles; therapeutic use; Male; Middle Aged; Piperazines; therapeutic use; Sulfones; therapeutic use; Triazines; therapeutic use; Vardenafil Dihydrochloride; Vasodilator Agents; therapeutic use; Yang Deficiency; drug therapy; Yin Deficiency; drug therapy
- From: National Journal of Andrology 2010;16(9):856-859
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the clinical efficacy of vardenafil on erectile dysfunction (ED) patients with kidney-yang deficiency, kidney-yin deficiency or liver-qi stasis.
METHODSBased on the syndromes of Traditional Chinese Medicine, 124 ED patients were divided into Groups A (kidney-yang deficiency, n=44), B (kidney-yin deficiency, n=41) and C (liver-qi stasis, n = 39). All the patients were treated with vardenafil at 5 mg daily for 8 weeks, and the therapeutic effects were evaluated by comparing the scores on IIEF-5 and Erection Quality Scale (EQS) before and after the treatment.
RESULTSAfter vardenafil treatment, the IIEF-5 and EQS scores of the ED patients were markedly increased, with statistically significant differences among the three groups (P < 0.01). The success rate of sexual intercourse was significantly improved in Groups A, B (P < 0.01) and C (P < 0.05). And the hardness of penile erection was enhanced by 81.82%, 73.17% and 43.59% respectively in the three groups of patients.
CONCLUSIONVardenafil is more effective for ED patients with kidney-yang or kidney-yin deficiency than for those with liver-qi stasis.
